JP2006501165A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006501165A5 JP2006501165A5 JP2004510817A JP2004510817A JP2006501165A5 JP 2006501165 A5 JP2006501165 A5 JP 2006501165A5 JP 2004510817 A JP2004510817 A JP 2004510817A JP 2004510817 A JP2004510817 A JP 2004510817A JP 2006501165 A5 JP2006501165 A5 JP 2006501165A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- composition
- subject
- exposed
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims 6
- 230000003115 biocidal effect Effects 0.000 claims 6
- 230000005779 cell damage Effects 0.000 claims 6
- 208000037887 cell injury Diseases 0.000 claims 6
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229940126575 aminoglycoside Drugs 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 231100000318 excitotoxic Toxicity 0.000 claims 2
- 230000003492 excitotoxic effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012825 JNK inhibitor Substances 0.000 description 7
- 229940118135 JNK inhibitor Drugs 0.000 description 6
- 102100023132 Transcription factor Jun Human genes 0.000 description 6
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 description 3
- 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 3
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 3
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 3
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 101100026251 Caenorhabditis elegans atf-2 gene Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 102000002569 MAP Kinase Kinase 4 Human genes 0.000 description 1
- 108010068304 MAP Kinase Kinase 4 Proteins 0.000 description 1
- 102100027584 Protein c-Fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/165,250 US20030108539A1 (en) | 2000-02-14 | 2002-06-07 | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| PCT/IB2003/003094 WO2003103698A1 (en) | 2002-06-07 | 2003-06-09 | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009272904A Division JP2010053136A (ja) | 2002-06-07 | 2009-11-30 | Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006501165A JP2006501165A (ja) | 2006-01-12 |
| JP2006501165A5 true JP2006501165A5 (enExample) | 2010-02-18 |
| JP4460445B2 JP4460445B2 (ja) | 2010-05-12 |
Family
ID=29732060
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004510817A Expired - Lifetime JP4460445B2 (ja) | 2002-06-07 | 2003-06-09 | Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤 |
| JP2009272904A Withdrawn JP2010053136A (ja) | 2002-06-07 | 2009-11-30 | Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009272904A Withdrawn JP2010053136A (ja) | 2002-06-07 | 2009-11-30 | Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20030108539A1 (enExample) |
| EP (7) | EP1911458B9 (enExample) |
| JP (2) | JP4460445B2 (enExample) |
| AT (2) | ATE417623T1 (enExample) |
| AU (1) | AU2003274820B2 (enExample) |
| CA (1) | CA2488695C (enExample) |
| CY (3) | CY1108847T1 (enExample) |
| DE (2) | DE60325429D1 (enExample) |
| DK (2) | DK1776958T5 (enExample) |
| ES (3) | ES2439950T3 (enExample) |
| HK (1) | HK1207971A1 (enExample) |
| PT (3) | PT1911458E (enExample) |
| SI (1) | SI1776958T1 (enExample) |
| WO (1) | WO2003103698A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US20040082509A1 (en) * | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| EP1656951A1 (en) * | 2004-11-12 | 2006-05-17 | Xigen S.A. | Conjugates with enhanced cell uptake activity |
| EP1661912A1 (en) * | 2004-11-29 | 2006-05-31 | Xigen S.A. | Fusion protein comprising a BH3-domain of a BH3-only protein |
| US20060223807A1 (en) | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
| US8080517B2 (en) * | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| EP2074138A4 (en) | 2006-09-19 | 2009-12-30 | Phylogica Ltd | NEUROPROTECTIVE PEPTIDE AP-1 SIGNALING INHIBITORS AND USES THEREOF |
| AU2008206077A1 (en) * | 2007-01-19 | 2008-07-24 | Kai Pharmaceuticals, Inc. | Modifications of peptide compositions to increase stability and delivery efficiency |
| WO2008154700A1 (en) * | 2007-06-20 | 2008-12-24 | Phylogica Limited | Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith |
| WO2009143864A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
| WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| EA201171188A1 (ru) * | 2009-03-30 | 2012-05-30 | Сантен Фармасьютикал Ко., Лтд. | Профилактическое или терапевтическое средство против болезни сетчатки и способ профилактики или лечения болезни сетчатки с использованием jnk (c-jun-аминоконцевая киназа)-ингибиторного пептида, а также применение указанного пептида |
| JP5457813B2 (ja) * | 2009-12-16 | 2014-04-02 | ルネサスエレクトロニクス株式会社 | Ａｄｐｌｌ回路、半導体装置及び携帯情報機器 |
| WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
| AU2010362444B2 (en) | 2010-10-14 | 2015-08-06 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
| WO2012112810A1 (en) * | 2011-02-18 | 2012-08-23 | Otonomy, Inc. | Prevention of and recovery from drug-induced ototoxicity |
| CN104023736A (zh) * | 2011-11-30 | 2014-09-03 | 埃克西金炎症有限公司 | Jnk信号转导途径的细胞-可渗透肽抑制剂用于治疗干眼综合征的用途 |
| WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| WO2014206426A1 (en) * | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| EA201501080A1 (ru) | 2013-06-26 | 2016-07-29 | Ксижен Инфлемейшн Лтд. | Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний |
| GB201719520D0 (en) * | 2017-11-24 | 2018-01-10 | Univ College Cardiff Consultants Ltd | Neuroprotectvie peptide |
| CN109182250A (zh) * | 2018-09-30 | 2019-01-11 | 山东省立医院 | 一种小鼠耳蜗毛细胞培养方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US817457A (en) * | 1906-01-18 | 1906-04-10 | Kelley M Turner | Head band or support for telephone-receivers. |
| US1447969A (en) * | 1922-05-12 | 1923-03-13 | Brandes Inc C | Telephone head set |
| US4048453A (en) * | 1976-02-11 | 1977-09-13 | Gustave Seidel | Telephone handset support device |
| US4631211A (en) * | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US5670617A (en) * | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
| DE4005783A1 (de) * | 1990-02-23 | 1991-09-05 | Andreas Suckert | Kopfhalterung fuer telefonhoerer |
| AU667244B2 (en) * | 1992-08-21 | 1996-03-14 | Biogen Idec Ma Inc. | Tat-derived transport polypeptides |
| ES2157225T3 (es) | 1992-10-09 | 2001-08-16 | Advanced Tissue Sciences Inc | Celulas hepaticas de reserva. |
| WO1996034093A1 (en) * | 1995-04-25 | 1996-10-31 | Baxter International Inc. | Composition containing collagenase and chymopapain for isolating hepatocytes and pancreatic islet cells |
| ATE365808T1 (de) | 1995-07-28 | 2007-07-15 | Marie Curie Cancer Care | Transportproteine und deren verwendungen |
| US5689558A (en) * | 1996-03-25 | 1997-11-18 | Osgood; Alan G. | Telephone handset holder |
| US5880261A (en) * | 1997-04-03 | 1999-03-09 | Waeber; Gerard | Transcription factor Islet-Brain 1 (IB1) |
| US5828749A (en) * | 1997-04-04 | 1998-10-27 | Brodskiy; Arkadiy | Phone holder kit |
| US6043083A (en) * | 1997-04-28 | 2000-03-28 | Davis; Roger J. | Inhibitors of the JNK signal transduction pathway and methods of use |
| EP0897002A3 (en) * | 1997-08-14 | 2001-10-04 | Smithkline Beecham Plc | U62317, a protein having a JNK-binding domain |
| EP0947524A1 (en) * | 1998-03-30 | 1999-10-06 | Upither B.V. | Novel peptides for the treatment of autoimmune diseases |
| AU3714499A (en) * | 1998-05-14 | 1999-11-29 | Pasteur Merieux Serums Et Vaccins | Hepatitis c virus mimotopes |
| CA2328457A1 (en) * | 1998-06-20 | 1999-12-29 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| KR100628847B1 (ko) * | 1998-09-25 | 2006-09-29 | 세파론, 인코포레이티드 | 감각 유모 세포 및 와우 뉴런의 손상의 예방 또는 치료 방법 |
| US6610820B1 (en) * | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| WO2001039784A1 (en) * | 1999-12-06 | 2001-06-07 | The General Hospital Corporation | Pancreatic stem cells and their use in transplantation |
| ES2386505T3 (es) * | 2000-10-17 | 2012-08-22 | Diatranz Otsuka Limited | Preparación y xenotrasplante de islotes de cerdo |
| WO2002081504A2 (en) * | 2001-04-06 | 2002-10-17 | Thomas Jefferson University | Multimerization of hiv-1 vif protein as a therapeutic target |
| DE10117281A1 (de) * | 2001-04-06 | 2002-10-24 | Inst Molekulare Biotechnologie | Peptid zur Diagnose und Therapie der Alzheimer-Demenz |
-
2002
- 2002-06-07 US US10/165,250 patent/US20030108539A1/en not_active Abandoned
-
2003
- 2003-06-09 EP EP07016361.3A patent/EP1911458B9/en not_active Expired - Lifetime
- 2003-06-09 AT AT06019172T patent/ATE417623T1/de active
- 2003-06-09 EP EP03740977A patent/EP1511507B1/en not_active Expired - Lifetime
- 2003-06-09 SI SI200331484T patent/SI1776958T1/sl unknown
- 2003-06-09 PT PT70163613T patent/PT1911458E/pt unknown
- 2003-06-09 CA CA2488695A patent/CA2488695C/en not_active Expired - Lifetime
- 2003-06-09 ES ES08021394.5T patent/ES2439950T3/es not_active Expired - Lifetime
- 2003-06-09 ES ES07016361.3T patent/ES2473274T3/es not_active Expired - Lifetime
- 2003-06-09 EP EP08021394.5A patent/EP2060265B1/en not_active Expired - Lifetime
- 2003-06-09 DE DE60325429T patent/DE60325429D1/de not_active Expired - Lifetime
- 2003-06-09 ES ES06019172T patent/ES2319454T3/es not_active Expired - Lifetime
- 2003-06-09 DK DK06019172.3T patent/DK1776958T5/da active
- 2003-06-09 PT PT80213945T patent/PT2060265E/pt unknown
- 2003-06-09 DK DK07016361.3T patent/DK1911458T5/da active
- 2003-06-09 EP EP06019172.3A patent/EP1776958B9/en not_active Expired - Lifetime
- 2003-06-09 PT PT06019172T patent/PT1776958E/pt unknown
- 2003-06-09 EP EP14001780.7A patent/EP2845603A1/en not_active Withdrawn
- 2003-06-09 AT AT03740977T patent/ATE372125T1/de not_active IP Right Cessation
- 2003-06-09 EP EP07023486A patent/EP1970070A3/en not_active Ceased
- 2003-06-09 DE DE60316149T patent/DE60316149D1/de not_active Expired - Lifetime
- 2003-06-09 JP JP2004510817A patent/JP4460445B2/ja not_active Expired - Lifetime
- 2003-06-09 EP EP12001707.4A patent/EP2532357A3/en not_active Withdrawn
- 2003-06-09 WO PCT/IB2003/003094 patent/WO2003103698A1/en not_active Ceased
- 2003-06-09 AU AU2003274820A patent/AU2003274820B2/en not_active Ceased
-
2009
- 2009-03-05 CY CY20091100251T patent/CY1108847T1/el unknown
- 2009-11-30 JP JP2009272904A patent/JP2010053136A/ja not_active Withdrawn
-
2013
- 2013-12-11 CY CY20131101120T patent/CY1114715T1/el unknown
-
2014
- 2014-04-15 CY CY20141100286T patent/CY1115331T1/el unknown
-
2015
- 2015-09-02 HK HK15108602.6A patent/HK1207971A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006501165A5 (enExample) | ||
| ES2732252T3 (es) | Procedimientos para tratar diabetes y/o promover la supervivencia de los islotes pancreáticos después del trasplante | |
| CZ20014289A3 (cs) | Nové pouľití sloučenin jako antibakteriálních činidel | |
| CA2442909A1 (en) | Multimerization of hiv-1 vif protein as a therapeutic target | |
| CA2488695A1 (en) | Cell-permeable peptide inhibitors of the jnk signal transduction pathway | |
| JP2018502836A5 (enExample) | ||
| BR0115965A (pt) | Composições farmacêuticas para a liberação oral de agentes farmacologicamente ativos | |
| CA2332817A1 (en) | Il-6 antagonist peptides | |
| WO2010107476A1 (en) | Inhibiting gsnor | |
| CN102016980A (zh) | 用于治疗癌症的胰岛素样生长因子结合蛋白7 | |
| WO2011149964A3 (en) | Methods for treating or preventing vascular graft failure | |
| SE9800550D0 (sv) | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof | |
| JP2011506436A (ja) | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| JP2005535588A5 (enExample) | ||
| TW200605897A (en) | Powder comprising new compositions of oligosaccharides and methods for their preparation | |
| JP2009530359A (ja) | 腫瘍成長の阻害 | |
| JP2025027020A (ja) | 患者において血清リン酸塩を低下させるための組み合わせ | |
| JPH0667832B2 (ja) | 腫瘍性疾患の治療に用いるプログルミド含有医薬組成物 | |
| CN100418532C (zh) | 治疗多种疾病的NF-κB化合物抑制剂 | |
| CA2374681A1 (en) | Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection | |
| JP2019108277A5 (enExample) | ||
| CN118909044A (zh) | 新型θ-防御素类似物 | |
| JPWO2021189104A5 (enExample) | ||
| JP2012504941A5 (enExample) | ||
| KR20090016595A (ko) | 항균성 펩티드의 발현을 회복시키기 위한 스핑고실포스포릴콜린 길항제의 용도 |